Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Medical Device

Nanjing Novlead Bio Files Hong Kong IPO – Nitric Oxide Therapy Specialist Targets Critical Care Market

Fineline Cube Mar 3, 2026
Company Deals

Boehringer Ingelheim Licenses Sitryx Autoimmune Program – $500M+ Deal for Oral Disease‑Modifying Therapy

Fineline Cube Mar 3, 2026
Company Deals

ArkBio Partners with Qilu Pharma on Azstarys China Commercialization – ADHD Therapy Market Entry

Fineline Cube Mar 3, 2026
Company Deals

QL Biopharma Raises 500M+ RMB Series C – OrbiMed Leads Round for Monthly GLP‑1 Zovigrutide

Fineline Cube Mar 2, 2026
Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Policy / Regulatory

NMPA CDE Launches “Caring Program – Extension” Pilot – Accelerates Rare Disease Drug Development Pathway

Fineline Cube Mar 2, 2026
Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Fineline Cube Mar 3, 2026
Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Fineline Cube Mar 3, 2026
Company Drug

Pfizer’s Ibrance Demonstrates Significant PFS Improvement in Phase III PATINA Trial

Fineline Cube Dec 13, 2024

US pharmaceutical major Pfizer Inc. (NYSE: PFE) and Alliance Foundation Trials, LLC (AFT) have announced...

Company Deals

BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039

Fineline Cube Dec 13, 2024

BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a significant licensing agreement...

Company Drug

Gan & Lee Pharmaceuticals Gets FDA Approval for GZR18 Obesity/Overweight Phase II Study

Fineline Cube Dec 13, 2024

China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced that it has received approval from...

Company Drug

HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Advanced Lung Cancer

Fineline Cube Dec 13, 2024

HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) has announced that its MET inhibitor, Orpathys (savolitinib),...

Company Drug

HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain

Fineline Cube Dec 13, 2024

China-based HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) is poised to receive another milestone payment...

Policy / Regulatory

National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs

Fineline Cube Dec 13, 2024

The preliminary outcomes of the 10th round of China’s national volume-based procurement (VBP) program were...

Company Medical Device

Grand Pharmaceutical Group Receives NMPA Approval for NOVASYNC HYBRID SYSTM

Fineline Cube Dec 13, 2024

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that it has received marketing...

Company Drug

HuidaGene Therapeutics Launches MUSCLE Study for CRISPR Therapy in Duchenne Muscular Dystrophy

Fineline Cube Dec 13, 2024

Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced the initiation of the MUSCLE study for...

Company Deals

Sunshine Lake Pharma Files for HKEX IPO, Expanding Global Pharmaceutical Reach

Fineline Cube Dec 13, 2024

China-based Sunshine Lake Pharma Co., Ltd has submitted an initial public offering (IPO) filing to...

Company Drug

Transcenta’s LIV-1 ADCs Show Promising Results in Pre-Clinical Breast Cancer Study

Fineline Cube Dec 13, 2024

China-based biotech company Transcenta Holdings Ltd (HKG: 6628) announced updated results from a pre-clinical study...

Company Deals

Mabwell Bioscience Secures Licensing Deal with TABUK Pharmaceutical for MENA Region

Fineline Cube Dec 12, 2024

China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has inked a licensing deal with TABUK...

Company Drug

ImmunoTech Biopharm’s CAR-T-19 Earns Breakthrough Therapy Designation for B-ALL Treatment

Fineline Cube Dec 12, 2024

China-based chimeric antigen receptor T-cell (CAR-T) specialist Immunotech Biopharm Ltd (HKG: 6978) has announced receiving...

Company Deals

Grand Pharmaceutical Group Secures Licensing Agreement for CORXEL’s Nasal Sprays in Greater China

Fineline Cube Dec 12, 2024

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced a significant licensing agreement with...

Company Deals

EOSVISION Ltd Secures Series A Funding to Advance Ophthalmic Implant Development

Fineline Cube Dec 12, 2024

Suzhou-based EOSVISION Ltd has reportedly raised close to RMB 100 million (USD 13.78 million) in...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-4729 Peptide Drug

Fineline Cube Dec 12, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical clearance from...

Company

VIVA Biotech Expands Global Footprint with New Boston Branch

Fineline Cube Dec 12, 2024

China-based Contract Research Organization (CRO) VIVA Biotech (HKG: 1873) has announced the inauguration of its...

Company Deals

Siemens Healthineers AG Acquires Advanced Accelerator Applications to Boost PETNET Solutions

Fineline Cube Dec 12, 2024

Germany-based Siemens Healthineers AG (ETR: SHL) has announced the completion of its acquisition of Advanced...

Company Deals

Angitia Biopharmaceuticals Secures USD 120 Million in Series C Financing for Musculoskeletal Treatments

Fineline Cube Dec 12, 2024

Angitia Biopharmaceuticals, a provider of solutions for musculoskeletal diseases operating out of Guangzhou, China, and...

Company Deals

MDHC Life Technologies Secures Series C++ Funding to Boost Consumer Healthcare and Life Sciences

Fineline Cube Dec 12, 2024

China-based Contract Development Manufacturing Organization (CDMO) MDHC Life Technologies (Kunshan) Co.,Ltd has reportedly raised hundreds...

Company

Bayer AG’s Shanghai Co.Lab to Host Epigenic Therapeutics and Peers for CGT Innovation

Fineline Cube Dec 12, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that Chinese companies Epigenic Therapeutics, Shanghai Immunocan Biotech...

Posts pagination

1 … 210 211 212 … 629

Recent updates

  • MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions
  • Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II
  • Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes
  • Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension
  • Xellsmart’s iPSC Neural Therapy Cleared by NMPA and FDA – First “Off‑the‑Shelf” Cell Therapy for MSA‑P Enters Clinic
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Medical Device

MicroPort Endovascular’s Hector Wins FDA Breakthrough Designation – Multi‑Branch Stent Graft Targets Complex Aortic Arch Lesions

Company Drug

Huadong Medicine’s DR30206 Wins NMPA Approval – Triple‑Target Fusion Protein for NSCLC Enters Phase II

Company Drug

Hua Medicine’s Dorzagliatin Wins Hong Kong Approval – First‑in‑Class GKA Enters Market for Type 2 Diabetes

Company Drug

Lepu Medical’s siRNA MWX401 Wins NMPA Approval – RNAi Therapy Targets Primary Hypertension

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.